Compare DBI & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBI | CNTX |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.7M | 116.7M |
| IPO Year | 1991 | 2021 |
| Metric | DBI | CNTX |
|---|---|---|
| Price | $7.26 | $1.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $7.25 | $5.67 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 12-09-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,892,654,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.18 | $0.49 |
| 52 Week High | $8.75 | $2.00 |
| Indicator | DBI | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.06 | 65.96 |
| Support Level | $7.64 | $1.46 |
| Resistance Level | $8.35 | $1.79 |
| Average True Range (ATR) | 0.54 | 0.17 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 23.33 | 56.59 |
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.